What side effects are associated with this type of intervention?

Radioligand therapy, such as [Lu-177]-PNT2002, used in treating metastatic castration-resistant prostate cancer (mCRPC), is generally well tolerated but can cause several side effects. Common adverse effects include myelosuppression (e.g., thrombocytopenia, lymphopenia, anemia, leukopenia), nephrotoxicity, and salivary gland toxicity (e.g., dry mouth, pain, swelling). Other treatments for prostate cancer, such as androgen receptor signaling inhibitors and taxane-based chemotherapy, can also lead to side effects like fatigue, nausea, and increased risk of infections due to bone marrow suppression. It is important for patients to discuss these potential side effects with their healthcare provider to manage and mitigate them effectively.

What prior FDA approvals exist?

The FDA has approved several treatments for prostate cancer that involve radioligand therapy, which delivers targeted radiation to cancer cells. Notably, lutetium Lu 177 vipivotide tetraxetan has been approved for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen-receptor pathway inhibitors and taxane-based chemotherapy. This approval was based on the VISION trial, which demonstrated significant improvements in progression-free survival and overall survival. Additionally, radium-223 (Ra-223) is another radiopharmaceutical approved for mCRPC, particularly for patients with symptomatic bone metastases and no known visceral metastatic disease.

What other types of research exist?

Promising alternatives to [Lu-177]-PNT2002 for prostate cancer treatment include: 1) [225Ac]-PSMA617, which uses targeted alpha therapy and has shown clinical potential in prostate cancer. 2) Radium-223, an alpha-emitting radiopharmaceutical approved for castration-resistant prostate cancer with bone metastases, demonstrating improved overall survival and reduced skeletal-related events. 3) Combination therapies involving [177Lu]-Dotatate, which have shown efficacy in neuroendocrine tumors and may be applicable to prostate cancer. These alternatives offer targeted radiation and have demonstrated promising results in clinical settings.

← Back to Search

Radioisotope Therapy

Lu-177 PSMA Therapy for Prostate Cancer (SPLASH Trial)

Phase 3

Waitlist Available

Research Sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Progression on previous treatment with one ARAT (abiraterone or enzalutamide or darolutamide or apalutamide) in either the CSPC or CRPC setting

Ineligible or averse to chemotherapeutic treatment options.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

SPLASH Trial Summary

This trial will test a new treatment for prostate cancer that has progressed after other treatments have failed. The goal is to see if it is effective and safe.

Who is the study for?

Men over 18 with advanced prostate cancer that's resistant to hormone therapy and has spread, despite previous treatments like abiraterone or enzalutamide. They should not want chemotherapy, have a low risk of AIDS (if HIV-positive), show signs of worsening cancer, and have proper organ function. Contraception is required for those with partners at risk of pregnancy.Check my eligibility

What is being tested?

The trial tests [Lu-177]-PNT2002 effectiveness in men whose prostate cancer worsened after second-line hormonal therapies. Participants will either receive this new treatment or continue with standard care options like abiraterone or enzalutamide as decided by the study team.See study design

What are the potential side effects?

[Lu-177]-PNT2002 may cause nausea, fatigue, dry mouth, reduced blood cell counts leading to increased infection risk or bleeding problems, kidney issues due to radiation exposure, and potential allergic reactions to its components.

SPLASH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer progressed after treatment with a specific hormone therapy.

Select...

I cannot or do not want to undergo chemotherapy.

Select...

My PSMA-PET scan results are positive.

Select...

I am fully active or can carry out light work.

Select...

My prostate cancer is getting worse despite treatment.

Select...

My cancer has grown by 20% or I have new cancer spots since starting treatment.

Select...

My kidney function is within the required range.

Select...

I will use effective birth control during the study and for 6 months after.

Select...

I am a man aged 18 or older.

Select...

I cannot or do not want to undergo chemotherapy.

Select...

My testosterone levels are very low.

Select...

My prostate cancer has been confirmed by a lab test.

Select...

My bone scan shows two or more new lesions indicating my bone disease is progressing.

SPLASH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Radiographic Progression Free Survival (rPFS)

Secondary outcome measures

Biochemical Progression-Free Survival (bPFS)

Duration of response

Objective Response Rate (ORR)

+2 more

Other outcome measures

Safety and Tolerability (AEs)

SPLASH Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: [Lu-177]-PNT2002 (Arm A)Experimental Treatment1 Intervention

[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)

Group II: Control Arm (Arm B)Active Control2 Interventions

Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).

0 / 13Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Radioligand therapy, such as [Lu-177]-PNT2002, targets prostate-specific membrane antigen (PSMA) on cancer cells, delivering localized radiation to destroy them while sparing surrounding healthy tissue. This targeted approach is crucial for prostate cancer patients as it potentially reduces side effects compared to traditional therapies. Other common treatments include androgen deprivation therapy (ADT), which reduces androgen levels to slow cancer growth, and chemotherapy, which uses drugs to kill rapidly dividing cells. Understanding these mechanisms helps in choosing the most effective and personalized treatment plan.

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.